NSEGeneral Updates15h ago · 1 Sept 2026, 12:04 pm

General Updates

Sakar Healthcare Limited · SAKAR

✦ AI Summary▲ PositiveOrder Win

Sakar Healthcare Limited has received 14 oncology product new approvals in the EU, UK, and Canada with 7 business partners, enhancing its coverage in treating various cancer types.

Analysis Scores

Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment9/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Sakar Healthcare Limited has informed the Exchange about Sakar receives 14 oncology product new approvals in the EU (Europe), UK & Canada with 7 business partners

Attachments (1)

📄

SAKAR_01092026120323_Announcement.pdf

pdf

Download →
View document text
Sakar Certified ISO 9001 :2015 by Healthcare Limited Corporate Office: 406, Silver Oaks Cornm. Complex, Opp.Arun Society, Paldi, Ahmedabad-380 007. Gujarat, India. Phone : 079-26584655 CINNo. : L24231GJ2004PLC04386I E-mail: info@sakarhealthcare.com Date: 1st Septem ber 2026 Web : www.sakarhealthcare.com The Manager Listing Compliance Department ational Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400051, India Symbol: SAKAR SUB: Sakar receives 14 oncology product new approvals in the EU (Europe), UK & Canada with 7 business partners Dear All, Sakar Healthcare Ltd. continues to make steady progress in its strategic initiatives, reflecting strong business momentum and positioning the company for sustained long-term growth. In this advancement: • Accord has been the front runner partner with another 5 products site variations to Sakar's manufacturing site approved by EMA- taking the count to total 6 of 8 technology transfer they initiated • Other 2 partners located in the UK and 1 in Germany have also successfully received approval of their 3 products from MHRA and EMA • Additionally 6 of Sakar's licensed out products have been granted Marketing Authorizations ofwhich 4 are in the EU, I each in the UK and Canada • These approvals have significantly enhanced the coverage to treating various cancer types including breast, lung, prostrate, stomach, head & neck, colon & rectum, ovary, liver, kidney, thyroid, blood, bone-marrow and lymph With this noticeable progress inthe regulated markets of the EU, UK & Canada, Sakar is well set to strengthen its position leveraging both the business models to gear up top-line sales. We do appreciate your encouragement, support and guidance during this formative phase. Thank you. Yours faithfully, FOR, SAKAR HEAt.~~::KE LIMITED BHARATSONI COMPLIANCE OFFI Regd. Office / Works: Block No.1 0-13, Sarkhej-Bavla Road, Village Changodar, Dist. Ahmedabad - 382 213. India. Phone : +91 99091 53977